Description: Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.
Home Page: www.geminalabs.com
3800 Westbrook Mall
Vancouver,
BC
V6S 2L9
Canada
Phone:
604-760-1997
Officers
| Name | Title |
|---|---|
| Ms. Brian Firth | Chief Exec. Officer |
| Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | Chief Financial Officer & Company Sec. |
| Robert Crandall Greene | Chief Technology Officer and Director |
| Mr. David Browning | Head of Productization & Director of Gemina Laboratories (UK) Limited |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.7011 |
| Price-to-Sales TTM: | 5789.8237 |
| IPO Date: | |
| Fiscal Year End: | January |
| Full Time Employees: | 5 |